NCT05704296 Saphenous Vein as Y-composite Versus Aortocoronary Conduit for CABG
| NCT ID | NCT05704296 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Ho Young Hwang |
| Condition | Coronary Artery Disease |
| Study Type | INTERVENTIONAL |
| Enrollment | 290 participants |
| Start Date | 2023-04-18 |
| Primary Completion | 2027-01-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 290 participants in total. It began in 2023-04-18 with a primary completion date of 2027-01-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Left internal thoracic artery (LITA) has been acknowledged as the first graft of choice for coronary artery bypass grafting (CABG). However, it is still not conclusive which one is the best second graft of choice among right internal thoracic artery, radial artery, right gastroepiploic artery, saphenous vein, and etc., as well as its configuration for CABG. In our institution, saphenous vein has been primarily used for the second graft and we have harvested it with 'No touch technique'. We have been demonstrated the excellent long-term patency of this 'No touch saphenous vein' in many studies. However, it is still unknown which configuration is the better strategy for the saphenous vein as a Y-composite graft based on the left internal thoracic artery versus an aortocoronary conduit. Thus, we aimed to evaluate morphologic change of saphenous vein graft by 1-year intravascular ultrasound (IVUS) study and angiographic patency results between Y-composite graft and aortocoronary conduit.
Eligibility Criteria
Inclusion Criteria: * A patient who is going to receive coronary artery bypass grafting * Older than 19 years * Coronary artery bypass grafting is going to be performed with left internal thoracic artery and saphenous vein graft Exclusion Criteria: * Other concomitant procedures (e.g. valve or aorta surgery) is planned * Patients with severe comorbidities which limit the life expectancy of them below 1 year (e.g. terminal cancer) * Patients whose left internal thoracic artery or saphenous vein is not available due to the low quality, severe injury, or absence of the graft * Patients whose ascending aorta is not suitable to aortocoronary anastomosis (e.g. ascending aorta aneurysm, porcelain aorta) * Emergency operation * Patients who have connective tissue disease * Reoperative coronary artery bypass grafting
Contact & Investigator
Ho Young Hwang, MD, PhD
PRINCIPAL INVESTIGATOR
Seoul National University Hospital
Frequently Asked Questions
Who can join the NCT05704296 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, studying Coronary Artery Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05704296 currently recruiting?
Yes, NCT05704296 is actively recruiting participants. Contact the research team at scalpel@snu.ac.kr for enrollment information.
Where is the NCT05704296 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT05704296 clinical trial?
NCT05704296 is sponsored by Ho Young Hwang. The principal investigator is Ho Young Hwang, MD, PhD at Seoul National University Hospital. The trial plans to enroll 290 participants.